About Glioblastoma

Glioblastoma (GBM) is the most aggressive and most common type of brain cancer. Previously referred to as glioblastoma multiforme, GBM is a malignant (cancerous) grade 4 tumor. Recurrence is very likely to occur and currently there is no standard of care treatment. Clinical trials are used to investigate potential new therapies and develop future treatments. 



Using our nanotechnology platform, Biodexa Pharmaceuticals is developing an experimental drug, called MTX110, for the treatment of recurrent glioblastoma (rGBM).

Biodexa Pharmaceuticals is proudly sponsoring non-profit organizations supporting patients with glioblastoma.

The Glioblastoma Research Organization is a 501I(3) nonprofit organization raising awareness and funds for cutting-edge research to find a cure for Glioblastoma, a rare malignant, fast-growing tumor affecting the brain or spine. The organization was established in 2018 and, to date, has provided support to doctors and researchers through five fully-funded projects, donating over $250,000 in the last two years. For additional information about the organization, funding and partners, please visit www.gbmresearch.org

Glioblastoma Research Organisation 

The American Brain Tumor Association (ABTA) is the oldest brain tumor organization in the US, founded 50 years ago. It’s mission is to advance the understanding and treatment of brain tumors with the goals of improving, extending, and ultimately saving the lives of those impacted by a brain tumor diagnosis. Our vision is a world where not one life is lost to a brain tumor. ABTA provides funding for research and a comprehensive set of services to support patients, caregivers, and loved ones. For more information, please visit 

www.abta.org

American Brain Tumor Association

Head for the Cure Foundation is a nonprofit organization based in Kansas City, MO, USA, that builds awareness, raises funds, and ignites hope & joy for those impacted by brain cancer, from survivors and patients to caregivers and those who have lost a loved one. Their nationwide 5K run/walks and other grassroots fundraisers help fund groundbreaking research and provide critical support to patients and families. Learn more at headforthecure.org

Head for cure

What does MAGIC-G1 hope to achieve?

The MAGIC-G1 clinical trial aims to understand whether the experimental treatment, MTX110, is safe in treating patients with recurrent glioblastoma (GBM).

Patients with primary (or newly diagnosed) glioblastoma are unfortunately not eligible to participate in this study. If you have just been diagnosed with glioblastoma, please speak with your treating physician about a possibility of joining one of many available studies that treat primary GBM patients.

This website is intended for residents of the USA only. This site does not provide medical advice. The site, content, and services do not provide any form of medical advice or recommendations and is provided for general information purposes only. For full disclaimer, please refer to the terms and conditions of use.